Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE
Authors:
Open Access
- 4 October 2023
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 12 (6) , 1845-1865
Abstract
Introduction Migraine is a common debilitating neurological disorder affecting a large proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, plays a key role in the pathophysiology of migraine, and the development of therapies targeting the anti-CGRP pathway has revolutionized the field of migraine treatment. Methods An expert task force of neurologists in the United Arab Emirates (UAE) developed and critically assessed recommendations on the use of CGRP-based therapies in migraine treatment and management in the UAE, based on available published literature. A consensus was reached for each statement by means of an open-voting process, based on a predefined agreement level of at least 60%. Results The consensus recommendations advocate the need for guidelines for the appropriate use of CGRP-based therapies by defining patient cohorts and appropriate monitoring of therapeutic response as well as standardizing the initiation, assessment, and cessation of treatment. The consensus recommendations were primarily formulated on the basis of international studies, because of the limited availability of regional and local data. As such, they may also act as guidelines for global healthcare providers. Conclusions These are the first consensus recommendations for the UAE that address the use of CGRP-based therapies in the treatment and management of migraine, integrating both clinical evidence and medical expertise to enhance clinical judgment and decision-making.Keywords
Funding Information
- Novartis Pharmaceuticals Middle East
This publication has 117 references indexed in Scilit:
- The pathophysiology of migraine: implications for clinical managementThe Lancet Neurology, 2018
- Fremanezumab for the Preventive Treatment of Chronic MigraineNew England Journal of Medicine, 2017
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysisCephalalgia, 2016
- Wiping Out CGRP: Potential Cardiovascular RisksTrends in Pharmacological Sciences, 2016
- Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b studyThe Lancet Neurology, 2015
- Detoxification in medication-overuse headache, a retrospective controlled follow-up study: Does care by a headache nurse lead to cure?Cephalalgia, 2015
- Calcitonin Gene-Related Peptide: Physiology and PathophysiologyPhysiological Reviews, 2014
- Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case–control studyArchives of Gynecology and Obstetrics, 2014
- Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraineNeurology, 2013